SCHEMBL6770619

SCHEMBL6770619

NC(=O)N(c1cccc(C(F)(F)F)c1)c1ccc(-c2ccc3ccccc3c2)cc1-c1nnn[nH]1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.35
PLG P00747 1/20 0.34
PLAU P00749 1/20 0.34
PLAT P00750 1/20 0.34
MTOR P42345 1/20 0.34
KAT6A Q92794 1/20 0.33
KIF11 P52732 1/20 0.33
CHEK2 O96017 1/20 0.33
ANO1 Q5XXA6 1/20 0.32
PTGDR2 Q9Y5Y4 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
CNR2 P34972 1/20 0.31
KDR P35968 1/20 0.31
SCN9A Q15858 2/20 0.31
DDR2 Q16832 2/20 0.31
HSD11B1 P28845 1/20 0.31
GRK6 P43250 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6775462 0.92 KIF11 (0.39) PARP1PLGPLAUPLATKIF11
SCHEMBL6775914 0.91 KIF11 (0.37) PARP1PLGPLAUPLATKIF11
SCHEMBL6775368 0.90 CNR2 (0.35) PARP1MTORPTGDR2RXFP1CNR2
SCHEMBL6781865 0.88 MAP2K4 (0.39) PARP1PLGPLAUPLATKIF11
SCHEMBL6776008 0.88 MAP4K4 (0.38) PLGPLAUPLATKIF11CHEK2
SCHEMBL6771095 0.87 NPBWR1 (0.34) PARP1KIF11CHEK2PTGDR2KDR
SCHEMBL6775671 0.86 IDH2 (0.36) KIF11CHEK2PTGDR2
SCHEMBL6782059 0.86 SCN9A (0.39) KIF11KDRSCN9A
SCHEMBL31337135 0.86 GPR35 (0.34) PARP1PTGDR2KDR
SCHEMBL6782022 0.86 GPR35 (0.34) PARP1PTGDR2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0977741-B1 SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE NEUROSEARCH AS (DK) 2003-09-03 EP claimed
US-6297261-B1 POTENT CHLORIDE CHANNEL BLOCKERS; TREATMENT OF SICKLE CELL ANEMIA, BRAIN EDEMA FOLLOWING ISCHAEMIA OR TUMORS, DIARRHEA, HYPERTENSION (DIURETIC), OSTEOPOROSIS, AND FOR THE REDUCTION OF THE INTRAOCULAR PRESSURE NEUROSEARCH A/S (DK) 2001-10-02 US claimed
US-6696475-B2 N-PHENYL-N'-(2-CARBOXYPHENYL) UREA, FOR EXAMPLE; CHLORIDE CHANNEL BLOCKERS; SUCH AS FOR TREATING BONE METABOLIC DISORDERS NEUROSEARCH A/S (DK) 2004-02-24 US disclosed
EP-0977741-B1 SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE NEUROSEARCH AS (DK) 2003-09-03 EP disclosed
US-20020037905-A1 Substituted phenyl derivatives, their preparation and use ANIONA APS (DK) 2002-03-28 US disclosed
US-6297261-B1 POTENT CHLORIDE CHANNEL BLOCKERS; TREATMENT OF SICKLE CELL ANEMIA, BRAIN EDEMA FOLLOWING ISCHAEMIA OR TUMORS, DIARRHEA, HYPERTENSION (DIURETIC), OSTEOPOROSIS, AND FOR THE REDUCTION OF THE INTRAOCULAR PRESSURE NEUROSEARCH A/S (DK) 2001-10-02 US disclosed
EP-0977741-A1 SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE NEUROSEARCH A/S (DK) 2000-02-09 EP disclosed
WO-1998047879-A1 SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE NEUROSEARCH A/S (DK) 1998-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037905-A1 Substituted phenyl derivatives, their preparation and use KCNB1, KCNH2, KCNJ2 PARP1 2413/4885PLG 3128/4885PLAU 4624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.